These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1121 related articles for article (PubMed ID: 34081806)

  • 1. COVID-19 vaccine-induced Stevens-Johnson syndrome.
    Dash S; Sirka CS; Mishra S; Viswan P
    Clin Exp Dermatol; 2021 Dec; 46(8):1615-1617. PubMed ID: 34081806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series.
    Vinay K; Kaushik A; Kumaran MS; Parsad D
    Dermatol Ther; 2019 Jul; 32(4):e12957. PubMed ID: 31070856
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Gilbert M; Scherrer LA
    Dermatol Ther; 2019 Jan; 32(1):e12758. PubMed ID: 30285308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic epidermal necrolysis in a patient with psoriatic arthritis.
    Pace J; Adami JZ; Mallia C; Mizzi A
    Adv Exp Med Biol; 1999; 455():557-60. PubMed ID: 10599399
    [No Abstract]   [Full Text] [Related]  

  • 5. The Consideration of Cyclosporine in the Treatment of Stevens-Johnson Syndrome.
    Malick H; Lauck K; Kivelevitch D
    JAMA Dermatol; 2024 Jan; 160(1):117. PubMed ID: 38055233
    [No Abstract]   [Full Text] [Related]  

  • 6. Sinopharm COVID-19 vaccine-induced Stevens-Johnson syndrome.
    Boualila L; Mrini B; Tagmouti A; El Moubarik N; Benchekroun Belabbes M; Boutimzine N; Cherkaoui LO
    J Fr Ophtalmol; 2022 Apr; 45(4):e179-e182. PubMed ID: 35033375
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARS-CoV-2 viral RNA.
    Tanaka A; Isei M; Kikuzawa C; Hinogami H; Nishida K; Gohma I; Ogawa Y
    J Dermatol; 2021 Mar; 48(3):e144-e145. PubMed ID: 33439527
    [No Abstract]   [Full Text] [Related]  

  • 8. An extremely rare mucocutaneous adverse reaction following COVID-19 vaccination: Toxic epidermal necrolysis.
    Mardani M; Mardani S; Asadi Kani Z; Hakamifard A
    Dermatol Ther; 2022 May; 35(5):e15416. PubMed ID: 35238119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case of erythema multiforme/Stevens-Johnson syndrome: an unusual presentation of COVID-19.
    Abdelgabar A; Elsayed M
    J R Coll Physicians Edinb; 2021 Jun; 51(2):160-161. PubMed ID: 34131675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort analysis.
    Curtis KK; Dillan MM; Sharma TR; Piktel J
    J Am Acad Dermatol; 2024 Jun; 90(6):1300-1302. PubMed ID: 38423469
    [No Abstract]   [Full Text] [Related]  

  • 11. [Blistering cutaneous lesions in a patient with systemic lupus erythematosis].
    Rodríguez M; Fernández-Espartero MC; Satué JA; de la Mata J
    Rev Clin Esp; 2001 May; 201(5):293-4. PubMed ID: 11458808
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19-induced toxic epidermal necrolysis.
    Narang I; Panthagani AP; Lewis M; Chohan B; Ferguson A; Nambi R
    Clin Exp Dermatol; 2021 Jul; 46(5):927-929. PubMed ID: 33511662
    [No Abstract]   [Full Text] [Related]  

  • 13. [Odinophagia and cutaneous lesions in patient with cerebral metastases].
    García Sánchez I; Chavarria Mur E; Avilés Izquierdo J; Molina Sánchez-Cabezudo F; Vera López E; Gilsanz Fernández C
    Rev Clin Esp; 2006 May; 206(5):251-3. PubMed ID: 16750112
    [No Abstract]   [Full Text] [Related]  

  • 14. The Consideration of Cyclosporine in the Treatment of Stevens-Johnson Syndrome-Reply.
    Miyamoto Y; Ohbe H; Yasunaga H
    JAMA Dermatol; 2024 Jan; 160(1):117-118. PubMed ID: 38055234
    [No Abstract]   [Full Text] [Related]  

  • 15. Stevens-Johnson syndrome precipitated by Moderna Inc. COVID-19 vaccine: a case-based review of literature comparing vaccine and drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Padniewski JJ; Jacobson-Dunlop E; Albadri S; Hylwa S
    Int J Dermatol; 2022 Aug; 61(8):923-929. PubMed ID: 35398905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
    Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP
    J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progressive epidermal and mucosal skin lesions in a patient with rheumatoid arthritis].
    Wittig Ch; Sanchez E; Shirahama J; Rüdt R
    Praxis (Bern 1994); 2007 May; 96(20):819-25. PubMed ID: 17566419
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of Steven-Johnson syndrome after COVID-19 vaccination.
    Mansouri P; Farshi S
    J Cosmet Dermatol; 2022 Apr; 21(4):1358-1360. PubMed ID: 35020263
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination.
    Larson V; Seidenberg R; Caplan A; Brinster NK; Meehan SA; Kim RH
    J Cutan Pathol; 2022 Jan; 49(1):34-41. PubMed ID: 34292611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept.
    Gavigan GM; Kanigsberg ND; Ramien ML
    J Cutan Med Surg; 2018; 22(5):514-515. PubMed ID: 29421925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.